KMO and schizophrenia: “KYNA hypothesis of schizophrenia” [16] was initiated by a discovery of KMO deficiency in Broadmann area of brain of schizophrenia patients (SP) [17], and was supported by findings of elevated KYNA concentrations in brains [18] and CSF [19] of SP and by observations of KYNA-induced schizophrenia-like symptoms in experimental animals [20], including disruption of pre-pulse inhibition [21] and impairment of cognitive functions [22], and damage of spinal cord myelin [23] and impairment of oligodendrocyte viability [24].